Acromegaly: pre-operative somatostatin analogues boost short-term cure rate

  • Yang C & al.
  • Sci Rep
  • 1 Oct 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Preoperative somatostatin analogues (SSAs) are associated with good safety and an improved short-term cure rate in patients with acromegaly receiving transsphenoidal surgery.

Why this matters

  • The role of preoperative SSAs in this patient group is controversial.

Key results

  • Patients who received SSAs had an improved short-term biochemical remission rate compared with those who did not receive SSAs (50.5% vs 35.1%; OR, 2.07; P<.00001 studies patients style="list-style-type:circle;">
  • 44.2% vs 15.6% (OR, 4.33; P=.005) for invasive macroadenomas (2 studies, 88 patients).
  • SSAs were not significantly associated with an improved long-term biochemical remission rate (65.8% vs 54.9%; OR, 1.49; P=.08; 5 studies, 397 patients).
  • SSAs were not associated with increased risk of postoperative complication (12.2% vs 11.1%; OR, 1.14; P=.67; 5 studies, 393 patients).
  • Study design

    • 12 studies (5 randomised controlled trials, 2 prospective studies, and 5 retrospective studies) were included in the meta-analysis.
    • Of 924 patients with acromegaly undergoing surgery, 445 received preoperative SSAs and 479 did not.
    • Funding: None disclosed.

    Limitations

    • Heterogeneity between included studies.
    • Potential selection bias in some included studies.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit